[{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"Multi-TLR","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"TLR4","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Paulson Investment Company, LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Private Placement","leadProduct":"INDP020","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Paulson Investment Company, LLC","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Paulson Investment Company, LLC"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Decoy20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ BeiGene","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ BeiGene"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Indaptus Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Decoy20","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Indaptus Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Indaptus Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Indaptus Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Indaptus Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : The collaboration aims to advance human clinical evaluation of the combination of BeiGene's anti-PD-1 antibody, Tevimbra (tislelizumab), with Indaptus’ Decoy20, a novel treatment for cancer.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 22, 2024

                          Lead Product(s) : Decoy20,Tislelizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : BeiGene

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20, an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          October 15, 2024

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20, an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 05, 2024

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Indaptus will fund its R&D activities, including Decoy20 (INDP020), a novel candidate that utilizes a multi-targeted approach to activate innate and adaptive immune responses against cancer cells.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          August 07, 2024

                          Lead Product(s) : INDP020

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Paulson Investment Company, LLC

                          Deal Size : $3.0 million

                          Deal Type : Private Placement

                          blank

                          05

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20, an intravenous infusion is designed to “re-set” the immune system’s response to cancer with multiple immune receptor agonist bacterial product in patients with advanced solid tumors.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          May 22, 2024

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy, which is being investigated for the treatment of patients with advanced solid tumors.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          September 19, 2023

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20 is a novel, systemically administered multiple Toll-like receptor (TLR) agonist-based cancer immunotherapy, which is being investigated for the treatment of patients with advanced solid tumors.

                          Brand Name : Decoy20

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          August 10, 2023

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20 received notice of allowance for a disease agnostic, composition and method of preparing patent. It has demonstrated the ability to eradicate established tumors in a murine model of various carcinoma in combination with either a NSAID or an anti-...

                          Brand Name : Decoy20

                          Molecule Type : Undisclosed

                          Upfront Cash : Not Applicable

                          May 09, 2023

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20 has demonstrated the ability to eradicate established tumors in a murine model of various carcinoma in combination with either a non-steroidal anti-inflammatory drug (NSAID) or an anti-PD-1 agent.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          April 17, 2023

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          BioFlorida Conference
                          Not Confirmed
                          BioFlorida Conference
                          Not Confirmed

                          Details : Decoy20 has demonstrated the ability to eradicate established tumors in a murine model of various carcinoma in combination with either a non-steroidal anti-inflammatory drug (NSAID) or an anti-PD-1 agent.

                          Brand Name : Decoy20

                          Molecule Type : Large molecule

                          Upfront Cash : Not Applicable

                          March 07, 2023

                          Lead Product(s) : Decoy20

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank